Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

por Fernández, Marcelo Sanmartín, Sánchez, Manuel Anguita, Arribas, Fernando, Barón-Esquivias, Gonzalo, Barrios, Vivencio, Cosin-Sales, Juan, Esteve-Pastor, María Asunción, Freixa-Pamias, Roman, Lekuona, Iñaki, Pérez-Cabeza, Alejandro I., Ureña, Isabel, Rodríguez, José Manuel Vázquez, Priu, Carles Rafols, Marin, Francisco
Publicado 2022

Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

por Sánchez, Manuel Anguita, Marín, Francisco, Masjuan, Jaime, Cosín-Sales, Juan, Rodríguez, José Manuel Vázquez, Barrios, Vivencio, Barón-Esquivias, Gonzalo, Lekuona, Iñaki, Pérez-Cabeza, Alejandro I., Freixa-Pamias, Román, Jimenez, Francisco Javier Parra, Khatib, Mohamed Monzer Khanji, Priu, Carles Rafols, Fernández, Marcelo Sanmartín
Publicado 2022